[1]RAZUMILAVA N, GORES GJ.Cholangiocarcinoma[J].Lancet, 2014, 383 (9935) :2168-2179.
|
[2]SU LH, ZHU XU, ZHANG LY.Diagnosis strategies for intrahepatic cholangiocarcinoma[J].J Clin Hepatol, 2017, 33 (1) :180-183. (in Chinese) 粟立红, 朱新宇, 张缭云.肝内胆管癌的诊断策略[J].临床肝胆病杂志, 2017, 33 (1) :180-183.
|
[3]LEI Z, XIA Y, SI A, et al.Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection[J].J Hepatol, 2017.[Epub ahead of print]
|
[4] WEI MY, ZHANG YY, GENG ZM, et al.Clinicopathological features and lymph node metastases characteristics of intrahepatic eholangiocarcinoma:A muhicenter retrospective study (A reporof 1321cases) [J].Chin J Dig Surg, 2018, 17 (3) :257-265. (in Chinese) 魏妙艳, 张园园, 耿智敏, 等.肝内胆管癌临床病理特征及淋巴结转移特点的多中心回顾性研究 (附1321例报告) [J].中华消化外科杂志, 2018, 17 (3) :257-265.
|
[5]WU XS, LIU YB.Progress on strategy of surgical treatment for intrahepatic cholangiocarcinoma[J].Chin J Dig Surg, 2016, 15 (11) :1131-1134. (in Chinese) 吴向嵩, 刘颖斌.肝内胆管细胞癌手术治疗策略的进展[J].中华消化外科杂志, 2016, 15 (11) :1131-1134.
|
[6]TAN JC, COBURN NG, BAXTER NN, et al.Surgical management of intrahepatic cholangiocarcinoma-a population-based study[J].Ann Surg Oncol, 2008, 15 (2) :600-608.
|
[7]BRIDGEWATER J, GALLE PR, KHAN SA, et al.Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma[J].J Hepatol, 2014, 60 (6) :1268-1289.
|
[8]KHAN SA, TOLEDANO MB, TAYLOR-ROBINSON SD.Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma[J].HPB (Oxford) , 2008, 10 (2) :77-82.
|
[9]SHAIB YH, DACILA JA, MCGLYN K, et al.Rising incidence of intrahepatic cholangiocarcinoma in the United States:A true increase?[J].J Hepatol, 2004, 40 (3) :472-477.
|
[10]PATEL T.Worldwide trends in mortality from biliary tract malignancies[J].BMC Cancer, 2002, 2:10.
|
[11]ENDO I, GONEN M, YOPP AC, et al.Intrahepatic cholangiocarcinoma:Rising frequency, improved survival, and determinants of outcome after resection[J].Ann Surg, 2008, 248 (1) :84-96.
|
[12]NATHAN H, ALOIA TA, VAUTHEY JN, et al.A proposed staging system for intrahepatic cholangiocarcinoma[J].Ann Surg Oncol, 2009, 16 (1) :14-22.
|
[13]SONBARE DJ.Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma:A multicenter study by the AFC-IHCC-2009 Study Group[J].Ann Surg, 2014, 259 (2) :e36.
|
[14]ZHOU SJ, HUANG ZY.Prognostic factors for tumor recurrence and metastasis of intrahepatic cholangiocarcinoma after radical resection[J].Chin J Gen Surg, 2014, 23 (8) :1024-1029. (in Chinese) 周少君, 黄志勇.肝内胆管癌根治性切除术后肿瘤复发转移的预后因素分析[J].中国普通外科杂志, 2014, 23 (8) :1024-1029.
|
[15]LEE TY, LEE SS, JUNG SW, et al.Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea:A case-control study[J].Am J Gastroenterol, 2008, 103 (7) :1716-1720.
|
[16]ZHOU YM, YIN ZF, YANG JM, et al.Risk factors for intrahepatic cholangiocarcinoma:A case-control study in China[J].World JGastroenterol, 2008, 14 (4) :632-635.
|
[17]SEKIYA S, SUZUKI A.Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes[J].J Clin Invest, 2012, 122 (11) :3914-3918.
|
[18]SHAIB YH, EI-SERAG HB, DAVILA JA, et al.Risk factors of intrahepatic cholangiocarcinoma in the United States:A case-control study[J].Gastroenterology, 2005, 128 (3) :620-626.
|
[19]SORENSEN HT, FRIIS S, OLSEN JH, et al.Risk of liver and other types of cancer in patients with cirrhosis:A nationwide cohort study in Denmark[J].Hepatology, 1998, 28 (4) :921-925.
|
[20]PALMER WC, PATEL T.Are common factors involved in the pathogenesis of primary liver cancers?A meta-analysis of risk factors for intrahepatic cholangiocarcinoma[J].J Hepatol, 2012, 57 (1) :69-76.
|
[21]GUO LH, XU HX.Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma:controversy over the ASSLD guideline[J].Biomed Res Int, 2015, 2015:349172.
|
[22]LIANG JJ, LI HC, LI XL, et al.The diagnosis value of CA19-9in different disease and tumor[J].Chin J Clin Ration Drug Use, 2010, 3 (9) :30-31. (in Chinese) 梁晶晶, 李红春, 李先莉, 等.CA19-9在不同病种和肿瘤中的诊断价值[J].临床合理用药杂志, 2010, 3 (9) :30-31.
|
[23]TAMANDL D, HERBERGER B, GRUENBERGER B, et al.Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma[J].Ann Surg Oncol, 2008, 15 (10) :2787-2794.
|
[24]CHEN JJ, LI WG.An excerpt of (2016) cholangiocarcinoma:Current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) [J].J Clin Hepatol, 2016, 32 (10) :1847-1850. (in Chinese) 陈嘉佳, 李文岗.《2016年欧洲胆管癌研究网络共识:胆管细胞癌研究现状及前景展望》摘译[J].临床肝胆病杂志, 2016, 32 (10) :1847-1850.
|
[25]JI LH, ZHAO G, WU ZY.Typing and staging and treatment of intrahepatic cholangiocarcinoma[J].Chin J Dig Surg, 2010, 9 (3) :193-196. (in Chinese) 季林华, 赵刚, 吴志勇.肝内胆管癌分型分期与治疗[J].中华消化外科杂志, 2010, 9 (3) :193-196.
|